Rest energy expenditure in Parkinson's disease: Role of disease progression and dopaminergic therapy
Rest energy expenditure in Parkinson's disease: Role of disease progression and dopaminergic therapy
复制标题
DOI：
10.1016/j.parkreldis.2012.10.016
复制
发表时间：
2013-02-01
影响因子：
4.1
通讯作者：
Ceravolo, Maria Gabriella
中科院分区：
文献类型：
--
作者：
Capecci, Marianna;Petrelli, Massimiliano;Ceravolo, Maria Gabriella
背景：体重减轻影响超过 50% 的帕金森病 (PD) 患者，并且与预期寿命缩短有关。其发病机制是多因素的，且PD代谢控制的机制尚未阐明。这项横断面研究旨在确定静息能量消耗 (REE)、PD 持续时间、Hoehn 82 Yahr (H&Y) 分期、药物治疗和体重指数 (BMI) 之间的关系，以确定体重减轻的可能预测因素。 方法：我们研究了 58 名 PD 受试者，排除已知影响代谢和体重的病症（严重震颤、运动障碍、痴呆、 发烧、持续感染、甲状腺疾病和吞咽困难）。受试者通过间接量热法在关闭状态（禁食 12 小时且停止用药）和开启状态（服用多巴胺能药物 60 分钟后）下进行 REE 测量。结果：关闭状态。在大多数 PD 患者中，REE 值与预期值（基于年龄、性别和 BMI）没有差异，H&Y IV 期受试者的 REE 值显着高于 H&Y II 期受试者（t = 3.5；p = 0.001）。疾病持续时间和硬度与 REE 增加显着相关 (r(2) = 0.31，F = 3.6；p = 0.0045）。开启状态。无论疾病持续时间或 H&Y 阶段如何，所有受试者的 REE 均下降约 8%。 BMI 与疾病持续时间和关闭状态下的 UPDRS 运动评分呈负相关，与开启状态下的 UPDRS 运动评分直接相关 (r(2) = 0.333，F = 3.5；p = 0.003）。 结论： 在 PD 中，REE 随着疾病持续时间而增加；它在体重指数下降中的不利作用似乎可以通过多巴胺能药物来补偿。 (C) 2012 Elsevier Ltd. 保留所有权利。
Background: Weight loss affects more than 50% of subjects suffering from Parkinson's Disease (PD) and is associated with reduced life expectancy. The pathogenesis is multifactorial and the mechanism of PD metabolism control is unresolved. This cross-sectional study aimed to ascertain the relationship between rest energy expenditure (REE), PD duration, Hoehn 82 Yahr (H&Y) stage, drug therapy and body mass index (BMI), in order to determine possible predictors of weight loss.Methods: We studied fifty-eight PD subjects, after excluding conditions with a known influence on metabolism and weight (severe tremor, dyskinesias, dementia, fever, on-going infections, thyroid disease, and dysphagia). Subjects underwent REE measurement, through indirect calorimetry, in both the OFF state (12 h fasting and off medications) and in the ON state (60 min after taking dopaminergic drugs).Results: OFF state. In the majority of PD patients REE values did not differ from those expected (based upon age, gender and BMI), being significantly higher in subjects in H&Y stage IV than H&Y stage II (t = 3.5; p = 0.001). Disease duration and rigidity were significantly associated with increased REE (r(2) = 0.31, F = 3.6; p = 0.0045). ON state. REE decreased by approximately 8% in all subjects, irrespective of disease duration or H&Y stage. BMI was inversely related to disease duration and UPDRS motor score in the OFF state and directly related to UPDRS motor score in the ON state (r(2) = 0.333, F = 3.5; p = 0.003).Conclusions: In PD REE increases as a function of disease duration; its adverse role in the decrease in BMI seems to be compensated for by dopaminergic medication. (C) 2012 Elsevier Ltd. All rights reserved.